Praxis Precision GC reports tax-share withholding

Praxis Precision Medicines General Counsel and Secretary Alex Nemiroff reported an automatic share withholding related to equity compensation.

Rhea-AI Filing Summary

Praxis Precision Medicines General Counsel and Secretary Alex Nemiroff reported an automatic share withholding related to equity compensation. On January 7, 2026, 89 shares of common stock were withheld by the company at a price of $292.63 per share to cover tax obligations tied to the vesting of previously reported restricted stock units. After this tax withholding event, Nemiroff beneficially owned 20,742.667 shares of Praxis Precision Medicines common stock, held directly.

Insider Trade Summary

Exercise Price or Tax Liability: 89 shares

Exercise Price or Tax Liability 1 txn

Insider Nemiroff Alex

Role General Counsel and Secretary

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	89	$292.63	$26K

Holdings After Transaction: Common Stock — 20,742.667 shares (Direct)

Footnotes (1)

1. F1. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PRAX General Counsel Alex Nemiroff report?

Alex Nemiroff reported that 89 shares of Praxis Precision Medicines common stock were withheld by the company to satisfy tax withholding obligations on vested restricted stock units.

Was the PRAX Form 4 transaction an open-market sale of shares?

No. The Form 4 notes that the Code F transaction involved shares withheld by the issuer to cover tax withholding for vesting restricted stock units, not a discretionary open-market sale.

How many PRAX shares were withheld and at what price?

The filing reports that 89 shares of Praxis Precision Medicines common stock were withheld at a price of $292.63 per share to satisfy tax obligations.

How many Praxis Precision Medicines (PRAX) shares does Alex Nemiroff own after this transaction?

Following the reported tax withholding, Alex Nemiroff beneficially owned 20,742.667 shares of Praxis Precision Medicines common stock, reported as held directly.

What does transaction code "F" mean in the PRAX Form 4?

Transaction code "F" indicates shares were withheld by the issuer to satisfy tax withholding obligations in connection with the vesting of equity awards such as restricted stock units.

What is Alex Nemiroff’s role at Praxis Precision Medicines (PRAX)?

According to the filing, Alex Nemiroff is an officer of Praxis Precision Medicines, serving as General Counsel and Secretary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 04:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nemiroff Alex

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		F(1)		89	D	$292.63	20,742.667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

Remarks:

	/s/ Alex Nemiroff	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.